GSK plc (LON:GSK) Receives Consensus Rating of "Moderate Buy" from Analysts
GSK plc has received a consensus rating of "Moderate Buy" from seven ratings firms covering the stock. One firm rated it a sell, one a hold, and five assigned a buy rating. The average target price among analysts is GBX 1,805.71. Recent ratings include Barclays with an "equal weight" rating at GBX 1,725, JPMorgan with an "underweight" rating, and Jefferies with a "buy" rating at GBX 2,100. GSK will pay a dividend of GBX 15 on October 10, 2023, making a yield of 0.97%.
GSK plc (LON:GSK - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is GBX 1,805.71 ($23.06).
- Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Several analysts recently weighed in on GSK shares. Barclays reiterated an "equal weight" rating and issued a GBX 1,725 ($22.03) price objective on shares of GSK in a research report on Tuesday, May 7th. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of GSK in a research report on Monday, July 29th. Jefferies Financial Group reissued a "buy" rating and issued a GBX 2,100 ($26.81) price objective on shares of GSK in a report on Thursday, June 27th. Berenberg Bank reaffirmed a "buy" rating and set a GBX 1,820 ($23.24) target price on shares of GSK in a research note on Wednesday. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on GSK from GBX 1,950 ($24.90) to GBX 1,850 ($23.62) and set a "buy" rating for the company in a research note on Wednesday, July 31st.
View Our Latest Report on GSK
Insider Transactions at GSK
- ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
In other news, insider Wendy Becker bought 446 shares of the business's stock in a transaction on Thursday, June 20th. The shares were bought at an average cost of GBX 1,614 ($20.61) per share, with a total value of £7,198.44 ($9,191.06). Insiders have bought a total of 462 shares of company stock valued at $744,868 over the last ninety days. Corporate insiders own 1.61% of the company's stock.
GSK Stock Performance
Shares of LON GSK opened at GBX 1,591 ($20.31) on Friday. The stock has a market capitalization of £64.91 billion, a P/E ratio of 1,407.96, a P/E/G ratio of 1.45 and a beta of 0.29. The firm's 50-day moving average price is GBX 1,552.78 and its two-hundred day moving average price is GBX 1,636.34. GSK has a 52-week low of GBX 1,340 ($17.11) and a 52-week high of GBX 1,823.50 ($23.28). The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04.
GSK Announces Dividend
- Back from the Dead, IBM’s Watson AI is Alive and Re-Emerging
The business also recently disclosed a dividend, which will be paid on Thursday, October 10th. Shareholders of record on Thursday, August 15th will be issued a dividend of GBX 15 ($0.19) per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a yield of 0.97%. GSK's payout ratio is presently 5,309.73%.
About GSK
(Get Free ReportGSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
See Also
- Five stocks we like better than GSK
- The Significance of Brokerage Rankings in Stock Selection
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- How to Calculate Options Profits
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- What Are Growth Stocks and Investing in Them
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ I’m giving you the name of this investment for free (From Porter & Company) (Ad)
Should you invest $1,000 in GSK right now?
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
